Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Intravesical injections of botulinum neurotoxin A to treat overactive bladder and/or detrusor overactivity related to multiple sclerosis: 5-Year continuation rate and specific risk factors for discontinuation-A study from the neuro-urology committee of the French Association of UrologyMult. Scler. 2023 Jun 02;[EPub Ahead of Print], S Delaval, PL Dequirez, C Hentzen, M Baron, E Mille, F Tariel, B Peyronnet, MA Perrouin-Verbe, A Pierache, E Chartier-Kastler, G Capon, JN Cornu, E Castel-Lacanal, X Gamé, G Karsenty, A Ruffion, P Denys, A Even, C Joussain, G Amarenco, V Phé, X Biardeau
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.